US/UK/Canada

Share

Quotes

Our effort to treat multiple myeloma is progressing with our lead candidate drug just entering into a phase 2 study, making it the ideal time for the company to broaden its pipeline to include other cancer indications and fully leverage our expertise in NK cell-therapy
Johan Liwing, CEO of XNK Therapeutics
Pick a time period -
Tags ( Active)

XNK Therapeutics to present at Redeye Regenerative Medicine/Cell Therapy event

XNK Therapeutics AB ("XNK”) today announced that Johan Liwing, CEO, will present the company at the Redeye Regenerative Medicine/Cell Therapy event on February 14.XNK’s presentation starts at 10:45 CET. The event will be broadcasted live starting at 09:00 CET and can be followed on Redeye’s homepage. XNK’s presentation will be followed by a short Q&A session. For more information, please contact: Johan Liwing, CEO, XNK Therapeutics Tel: +46 706 70 36 75 E-mail: johan.liwing@xnktherapeutics.com About XNK Therapeutics AB XNK Therapeutics is a clinical stage immunotherapy

XNK Therapeutics receives EMA scientific recommendation for evencaleucel as an Advanced Therapy Medicinal Product

XNK Therapeutics AB (“XNK”) today announced that evencaleucel has received a scientific recommendation from the Committee for Advanced Therapies (CAT) of the European Medicines Agency (EMA). This recommendation classifies evencaleucel as a Somatic Cell Therapy Medicinal Product (sCTMP) within the category of Advanced Therapy Medicinal Products (ATMPs).XNK’s platform, which is used for the manufacturing of evencaleucel, has ideal properties to produce autologous NK cell-based drug candidates for targeting malignant diseases across a wide range of indications in mono- and combination therapy.

XNK Therapeutics to present at DNB Nordic Healthcare Conference in Oslo

XNK Therapeutics AB today announced that Johan Liwing, CEO, will present the company at the DNB Nordic Healthcare Conference in Oslo, Norway, on December 14 at 10:15am CET.The presentation is followed by a short Q&A session, moderated by a DNB analyst.     For more information, please contact: Johan Liwing, CEO, XNK Therapeutics Tel: +46 706 70 36 75 E-mail: johan.liwing@xnktherapeutics.com     About XNK Therapeutics AB XNK Therapeutics is a clinical stage immunotherapy company focused on bringing new and more effective treatments to cancer patients. The

XNK Therapeutics to present at Investival Showcase Meeting

XNK Therapeutics AB ("XNK”) today announced that Johan Liwing, CEO, will present the company at the at Investival Showcase Meeting in London, on November 13[th]The LSX Investival Showcase meeting is one of Europe’s biggest pitch events for early and growth stage companies. The meeting brings together over three hundred qualified life science investors. In addition, it serves as the kickoff to the Jefferies week, leading into the Jefferies London Healthcare Conference, where XNK will also participate. The presentation is followed by a short Q&A session. For more information, please

XNK Therapeutics announces poster presentations at the 38[th] Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

XNK Therapeutics AB (”XNK”) participates in the SITC meeting, which takes place in San Diego, USA, and will present the latest research relating to the company’s leading natural killer (NK) cell therapies. Two abstracts have been accepted for presentation at the meeting.The first poster, titled Harnessing the Potential of Autologous NK Cells for Immune Therapy of Patients with Advanced Bladder Cancer, describes the successful expansion of autologous NK cells from peripheral blood mononuclear cells (PBMCs) from bladder cancer patients. Results demonstrate that NK cells from patients before

XNK Therapeutics receives funding from Sweden’s innovation agency Vinnova

XNK Therapeutics AB (“XNK”) today announced that it has applied for and been granted funding by Sweden’s innovation agency Vinnova. The grant consists of SME support through the Competence Center for Next-generation NK Cell-based Cancer Immunotherapy (NextGenNK). The competence center is coordinated by the Karolinska Institutet and XNK has been a member since the center’s inception in 2020. The funding amounts to up to 1.7 million SEK over two years and will be used in a specific preclinical program in XNK’s project portfolio. For more information, please contact: Johan Liwing, CEO,

XNK Therapeutics to present at 2[nd] Annual Innate Killer Europe Summit in October

XNK Therapeutics AB today announced that Anna-Karin Maltais, Chief Scientific Officer, will be speaking at the 2[nd] Annual Innate Killer Europe Summit in London on October 18.The meeting is the second Innate Killer Europe Summit following last year’s first European version of the larger annual US Innate Killer Summit. The purpose of the meeting is to build community and collaboration to leverage innovative European R&D and transform the innate immune space. The summit gathers 80+ key European natural killer, natural killer T, neutrophil, gamma delta T and macrophage thought leaders to

XNK Therapeutics presented two posters at the NK2023 conference in Oslo

XNK Therapeutics AB today announced that two posters, regarding bladder cancer (BC) and acute myeloid leukemia (AML) respectively, was presented at the 20[th] Meeting of the Society for Natural Immunity (NK2023) in Oslo, Norway, in September.XNK Therapeutics participate at NK2023 in Oslo and present the latest research relating to the company’s leading natural killer (NK) cell therapies. Two abstracts have been accepted for presentation at the meeting. The poster on BC shows the feasibility of expanding autologous NK cells from peripheral blood mononuclear cells (PBMCs) from BC patients.

XNK Therapeutics to present at the 8th CAR-TCR Summit in Boston

XNK Therapeutics AB (“XNK”) today announced that Linda Brick, Head of QA, will be speaking at the 8th CAR-TCR Summit in Boston.The annual CAR-TCR Summit is the world’s pre-eminent industry-leading comprehensive forum that unites the global cell therapy community across a variety of cell types (αβ T, γδ T, NK, NKT, Macrophage, TIL and more), Over 1000 experts from both pharmaceutical companies, including autologous and allogeneic cell therapy drug developers, and academia participate to advance the field. On August 30, Linda Brink will present XNK and talk about improving training and

XNK Therapeutics enters into research collaboration with Karolinska University Hospital in acute myeloid leukemia (AML)

XNK Therapeutics AB (“XNK”) today announced that the company has entered into a research collaboration with the Karolinska University Hospital, Sweden, to evaluate the suitability of the company’s autologous natural killer (NK) cell therapy candidate XNK02 as a novel therapy for treatment of acute myeloid leukemia (AML).In collaboration with Karolinska University Hospital, XNK will perform a large-scale bioreactor culture study of AML patients’ immune cells. These cells will be activated and expanded using XNK’s proprietary technology. The study aims to further investigate the expansion

XNK Therapeutics to present two posters at the NK2023 conference in Oslo in September

XNK Therapeutics AB today announced that two posters, regarding bladder cancer and Acute Myeloid Leukemia (AML) respectively, will be presented at the 20[th] Meeting of the Society for Natural Immunity (NK2023) in Oslo, Norway, in September.XNK Therapeutics will participate at NK2023 in Oslo in September and present the latest research relating to the company’s leading natural killer (NK) cells therapies. Two abstracts have been accepted for presentation at the meeting. The data have been generated in collaboration with XNK’s external partners, Anders Ullén and Fernanda Costa Svedman at

XNK Therapeutics enters into agreement with US-based biotechnology company

XNK Therapeutics AB (“XNK”) today announced that the company has entered into an agreement with a US biotechnology company. Under the agreement the parties will perform preclinical evaluation of XNK’s autologous NK cell therapy candidate XNK02 in combination with a drug candidate currently in clinical development by the US company. The combination will initially be tested against acute myeloid leukemia (AML). The collaboration supplements XNK’s current collaborations in the field of AML with the University of Texas MD Anderson Cancer Center. For more information, please contact:

XNK Therapeutics to present two abstracts at the Society for Immunotherapy of Cancer’s meeting in San Diego in November

XNK Therapeutics AB today announced that the abstracts Harnessing the potential of autologous NK cells for immunotherapy of patients with advanced bladder cancer and Feeder-Free Expansion of Autologous Cytotoxic NK Cells for Acute Myeloid Leukemia Treatment will be presented at the 38[th] Meeting of the Society for Immunotherapy of Cancer (SITC) in San Diego in November.XNK Therapeutics will participate at the SITC meeting in San Diego in November and present the latest research from the company’s leading preclinical projects in bladder cancer and acute myeloid leukemia (AML). Two abstracts

XNK Therapeutics one of three winners of Business Sweden’s Catalyst program 2023

XNK Therapeutics AB today announced that it has been selected as one of three winners of Business Sweden’s Catalyst program 2023. The program identifies Swedish companies having the strongest prerequisites to scale up globally.“We are very grateful to be recognized as one of the most promising Swedish companies by the Catalyst committee. XNK Therapeutics is a pioneer in the development of autologous natural killer (NK) cell-based cancer therapies, with a pipeline consisting of both solid tumor and blood cancer programs. We are looking forward to working with the team from Business Sweden in

XNK Therapeutics appoints Hugo Petit as Chief Financial Officer

XNK Therapeutics today announced the appointment of Hugo Petit as Chief Financial Officer (CFO) and member of the company’s leadership team. Hugo Petit has extensive experience in the life sciences sector and has served as CFO in both public and privately held companies.“We are very pleased to have Hugo join us as XNK’s new CFO. His wealth of financial experience, particularly in the life sciences sector, will strengthen the organization as we continue to grow the company“, said Johan Liwing, CEO of XNK Therapeutics.  Hugo Petit has held senior positions within finance and business

XNK Therapeutics to present at ABG Sundal Collier’s Life Science Summit in Stockholm

XNK Therapeutics today announced that its CEO Johan Liwing will present at ABG Sundal Collier’s Life Science Summit in Stockholm, Sweden, on May 31 at 10:00am CEST.The presentation is followed by a short Q&A session, moderated by an ABGSC analyst, and a recording will be available after the event. For more information, please contact: Johan Liwing, CEO, XNK Therapeutics Tel: +46 706 70 36 75 E-mail: johan.liwing@xnktherapeutics.com About XNK Therapeutics AB XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by

XNK Therapeutics Enters into Research Agreement with Global Pharma Company

XNK Therapeutics AB (“XNK”) today announced that the company’s autologous natural killer (NK) cell therapy candidate XNK04 will be evaluated in combination with an ADCC competent PD-L1 inhibitor in liver cancer under a research agreement with a global pharma company.The preclinical validation study aims to test the cell therapy candidate XNK04 alone and in combination with an antibody checkpoint inhibitor against autologous cancer cells isolated from patients with hepatocellular carcinoma (HCC). The study will provide data to support initiation of a potential future clinical phase I/II

XNK Receives EU Tissue Establishment Certificate

XNK Therapeutics today announced that it has been approved as an EU Tissue Establishment. This certificate allows the company to take control of the complete manufacturing chain, from withdrawal of blood from the patient at the clinic to the delivery of the finished autologous NK-cell based medicinal product.“This is another very important milestone for us. From a manufacturing viewpoint, we now have all the permits we need to launch clinical studies within EU. All building blocks are now completed to position us for significant value creation with three to four potential phase I/II

XNK presents at the 8[th] Innate Killer Summit in La Jolla, San Diego

XNK Therapeutics AB today announced its extensive participation at the 8[th] Annual Innate Killer Summit in La Jolla, San Diego, CA, March 28-30.The Annual Innate Killer Summit is the largest and leading technical, industry-focused, end-to-end innate immune cell therapy meeting to explore frontiers in immunobiology, genetic modification, clinical translation, scalable manufacturing, cryopreservation, and CMC. Over 200 experts from both pharmaceutical industry and academia participate to advance the clinical and phase development of NK, macrophage, γδT and NKT cell therapies for liquid and

XNK receives certificate of GMP compliance of a manufacturer from the Medical Products Agency

XNK Therapeutics today announced that it has received a GMP manufacturing license and a certificate of GMP compliance from the Swedish Medical Products Agency, which means that the company can produce at scale for its planned clinical studies.“We are very happy to receive this license. It is an important milestone for XNK, and we are now well positioned for significant value creation with three to four potential phase I/II readouts in our pipeline over the coming three years. The in-house GMP facility provides us with valuable capacity, flexibility and control over our clinical

XNK Therapeutics to present at Redeye’s Regenerative Medicine/Cell Therapy event on February 22

XNK Therapeutics AB’s CEO Johan Liwing will present at Redeye’s Regenerative Medicine/Cell Therapy event on February 22 between 09:00-12:00 CET.XNK’s presentation starts at 09:10 and is followed at 09:55 by a panel discussion regarding cell therapy for cancer. The presentation is broadcasted live starting at 09:00 and can be followed at: https://www.redeye.se/events/868745/redeye-theme-regenerative-medicine-cell-therapy-2 For more information, please contact: Johan Liwing, CEO, XNK Therapeutics Tel: +46 706 70 36 75 E-mail: johan.liwing@xnktherapeutics.com About XNK

XNK Therapeutics appoints Dr. Peter Hovstadius as CMO

XNK Therapeutics AB (“XNK”) today announced the appointment of Dr. Peter Hovstadius as Chief Medical Officer (CMO), effective immediately. Dr. Hovstadius will be a member of the company’s management team. Dr. Johan Aschan who retires from his position as CMO will continue as the company’s Senior Medical Advisor.Dr. Hovstadius received his MD from Uppsala University in 1992 and his PhD in Preclinical and Clinical Development of the Novel Cyanoguanidine CHS 828 for Cancer Treatment in 2005.  He is also a specialist in Clinical Pharmacology. During his career, he has held Medical Director

First patient cells collected in XNK’s preclinical bladder cancer study

XNK Therapeutics AB (“XNK”) today announced that the first patient has donated cells in the recently initiated preclinical evaluation of the autologous NK cell product XNK03 in locally advanced or metastatic urothelial cancer. The study is performed in collaboration with Anders Ullén’s research group at the Karolinska University Hospital, Stockholm, Sweden.This is the company’s first solid tumor indication and complements the ongoing Phase II clinical study in multiple myeloma (MM) and the preclinical proof-of-concept study in acute myeloid leukemia (AML) using patient samples from The

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe